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Abstract
Background: This phase II study assessed the response rate and toxicity profile of weekly paclitaxel and
capecitabine in patients with metastatic or recurrent squamous cell carcinoma of the esophagus (SCCE)
Methods: Patients with histologically confirmed SCCE were treated with paclitaxel 80 mg/m
2 intravenously on
days 1 and 8 plus capecitabine 900 mg/m
2 orally twice a day on days 1-14. Treatment cycles were repeated every
3 weeks until disease progression or unacceptable toxicity.
Results: Between 2006 and 2009, 32 patients were enrolled. Twelve patients were chemotherapy-naïve. Twenty
patients had received prior chemotherapy including platinum-based regimens. Patients received a median of 5
cycles of treatment (range, 1-12). The response rate was 75% (95%CI; 50.5~99.5%) in the first-line and 45% (95%CI;
26.9~73.1%) in the second-line. With a median follow-up of 20.7 months, median progression-free survival was 5.2
months (95% CI, 4.0 to 6.4) for all patients and median overall survival (OS) was 11.7 months (95% CI, 5.5 to 18.0)
for all patients. The median OS was 14.3 months (95% CI, 10.6 to 18.0) for patients receiving therapy as 1
st line and
8.4 months (95% CI, 6.6 to 10.1) for those receiving as 2
nd-line therapy. Grade 3/4 neutropenia was observed in
53.3% of the patients, which was the most common cause of dose reduction. G3 non-hematologic toxicity
included stomatitis (9.4%), asthenia (6.3%), and hand-foot skin reaction (3.1%).
Conclusions: Weekly paclitaxel and capecitabine is a highly active and well-tolerated regimen in patients with
metastatic or recurrent SCCE in the first-line as well as second-line setting.
Keywords: paclitaxel, capecitabine, squamous cell carcinoma of the esophagus
Background
Esophageal cancer is characterized by poor prognosis,
with 50% of patients presenting with metastatic disease
at the time of diagnosis. In the remaining 50% of
patients presenting initially with loco-regional disease,
systemic metastatic disease will develop in the vast
majority. The prognosis for patients diagnosed with
advanced esophageal cancer is poor with a 5-year survi-
val of 10-15% from diagnosis [1]. Conventional single
agents active in esophageal cancer include cisplatin, 5-
FU, etoposide, and mitomycin, with response rates ran-
ging from 15% to 25% [1-4]. The two-drug combination
of cisplatin and 5-FU has been the standard regimen for
two decades, with a 25-35% response rate in metastatic
disease. However, complete responses are rare, median
duration of response is usually short, and the median
survival time is only 6-10 months [5]. New regimens
such as paclitaxel-cisplatin-5FU and irinotecan-cisplatin
have shown promising anti-tumor activity in phase II
trials [2,6]. Since first-line therapies are not curative,
patients eventually experience disease progression. Once
t h ed i s e a s ep r o g r e s s e s ,t h em edian survival time is very
short. No regimen can be considered as standard in the
second-line setting. Thus, patients with good perfor-
mance status are candidates for clinical trials exploring
further treatment options.
Paclitaxel is used at a dose range of 135 to 200 mg/m
2
over 3 hours in patients with other solid tumors such as
non-small cell lung cancer. However, toxicities have
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paclitaxel showed comparable efficacy to that of 3-
weekly paclitaxel, while having a lower incidence of
myelosuppression and neurotoxicity [7,8].
Capecitabine is an orally administered fluoropyrimi-
dine that is converted by 5-FU by thymidine phosphory-
lase (TP), preferentially in tumor tissues and has
demonstrated activity as single agent in patients with
gastrointestinal cancers. The tumor selectivity of capeci-
tabine has been documented in clinical studies, where
administration of capecitabine has been shown to result
in approximately 2.5 times higher concentrations of 5-
FU in the tumor tissue than in normal tissues [9]. Orally
administered capecitabine mimics continuous-infusion
of 5-FU, is well tolerated, with hand-foot syndrome and
diarrhea the most common toxicities reported, and is
more convenient for patients.
Taxanes upregulate the activity of TP in mouse mam-
mary tumor cells in vitro and in xenograft models [10].
This taxane-mediated upregulation is synergistic, time
dependent, and persists for up to 10 days. Thus, sequen-
tial administration of taxanes followed by capecitabine
could result in enhanced efficacy of capecitabine. The
different toxicity profiles of the two drugs and preclini-
cal synergy provide the rationale for evaluating the com-
bination of capecitabine with paclitaxel clinically. Also,
taxanes plus capecitabine were reported to be highly
active against non-small cell lung cancer [11], breast
cancer [12], and gastric cancer [13]. Schedule optimiza-
tion based on the upregulation of TP may result in a
greater therapeutic index, thus allowing for the determi-
nation of the most advantageous way of combining
these agents. In preclinical experiments, upregulation of
TP activity was noted within 4 days of taxane treatment,
and the effect was maximal at about 6-8 days [10].
Hence, a weekly schedule of paclitaxel would provide
improved synergy for administration in combination
with capecitabine. Considering synergistic activity and
the different toxicity profiles of paclitaxel and capecita-
bine, we conducted a phase II trial evaluating the effi-
cacy and safety in patients with esophageal squamous
cell carcinoma.
Methods
1. Study Population
Patients with metastatic or recurrent squamous cell car-
cinoma of the esophagus that had been histologically
confirmed were eligible. Additional inclusion criteria
were as follows; 1) at least 18 years old, 2) ECOG per-
formance status of 0 to 2, 3) measurable lesions defined
as RECIST 1.0, 4) adequate bone marrow, hepatic, and
renal functions, defined as WBC ≥ 3,500/mm
3,a b s o l u t e
neutrophil count (ANC) ≥ 1,500/mm
3, platelets ≥
100,000/mm
3, ALT or AST < 2.5 times the upper
normal limit, bilirubin ≤ 1.5 times the upper normal
limit, and serum creatinine ≤ 1 . 5m g / d L ,5 )n op r i o r
radiotherapy to measurable lesions. Patients were
excluded if there was severe co-morbidity such as myo-
cardial infarction within preceding 6 months or sympto-
matic heart disease including unstable angina,
congestive heart failure, or uncontrolled arrhythmia, and
serious concomitant infection. Patients unable to swal-
low the capecitabine tablets were also excluded, even
after placement of a stent.
Written informed consent approved by the Institu-
tional Review Board of National Cancer Center was
obtained from all patients prior to entering the study.
The study followed the Declaration of Helsinki and
good clinical practice guidelines. This study is registered
with http://ClinicalTrials.gov (identifier; NCT00453323).
2. Treatment
Paclitaxel (Padexol
®) was provided by Shinpoong phar-
maceutical company and capecitabine (Xeloda
®)w a s
provided by Roche. Treatment was given in the outpati-
ent setting. It consisted of paclitaxel 80 mg/m
2 intrave-
nously on days 1 and 8 and capecitabine 900 mg/m
2
orally twice a day on days 1-14 followed by a 1 week
rest period. The Treatment cycle was repeated every 3
weeks, until disease progression or unacceptable toxicity.
Patients were premedicated with dexamethasone 20 mg,
pheniramine maleate 45.5 mg, and famotidine 20 mg, 30
minutes before administration of paclitaxel. For practical
reasons, capecitabine doses were rounded to the nearest
dose that could be administered with a combination of
500-mg and 150-mg tablets of drug. Capecitabine was
given approximately 12 hours apart and taken orally
with water within 30 minutes after ingestion of food.
Capecitabine doses were interrupted in patients with
grade 3 or 4 diarrhea or other non-hematologic toxici-
ties and were reduced for subsequent cycles. The pacli-
taxel dose on day 8 was reduced to 75% in patients with
an absolute neutrophil count (ANC) of 0.5 to 0.99 ×
10
9/L and was omitted in patients with an ANC ≤ 0.5 ×
10
9/L; the dose was reduced to 50% for grade 3 non-
hematologic toxicities and was omitted for grade 4
adverse events.
3. Dose Modifications for Adverse Events
Toxicity was evaluated before each treatment cycle
according to the National Cancer Institute Common Toxi-
city Criteria (NCI CTC), version 3.0. To begin the next
treatment cycle, each patient was required to have an
absolute neutrophil count (ANC) ≥ 1.5 × 10
9/L, a platelet
count ≥ 100 × 10
9/L and resolution of clinically significant
non-hematological adverse events to grade 1 or 0.
Treatment was continued at the same dose, without
interruption or dose reduction, in patients experiencing
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become serious or life threatening (e.g., alopecia). For all
other treatment-related adverse events of grade 2 or
higher, a dose modification scheme was implemented.
Dose reduction was not required following the first
appearance of any grade 2 toxicity, although treatment
was delayed until the toxicity had resolved to grades 0-
1. Treatment with both agents was interrupted and the
dose of both agents was reduced by 20% in patients who
experienced a second occurrence of any grade 2 toxicity
or at the first occurrence of any grade 3 toxicity. If
patients experienced a third occurrence of any grade 2
toxicity or a second occurrence of any grade 3 toxicity,
treatment was interrupted/delayed until the toxicity
resolved to grades 0-1 and the dose of both agents was
further reduced by 20% of the previous dose. Treatment
with both agents was discontinued if any grade 2 toxi-
city occurred for a fourth time or any grade 3 toxicity
for a third time despite dose reduction. Treatment was
discontinued if patients experienced a grade 4 non-
hematologic toxicity. Paclitaxel was discontinued and
capecitabine treatment was modified according to the
scheme outlined above in patients with grade 3 periph-
eral neuropathy. The paclitaxel dose was reduced by
20% for patients who developed grade 4 neutropenia for
more than 5 days or neutropenic fever.
4. Statistical Analysis
The primary objective of this study was to evaluate the
response rate of paclitaxel plus capecitabine as second-
line therapy in patients with metastatic or recurrent eso-
phageal cancer. With the regard to the definition of
therapy-line, the surgery and radiotherapy was not
counted as therapy-line, only number of palliative che-
motherapy was counted.
The Simon’s two-stage optimal design was used for
determining the total number of patients required for
this phase II study. We set an overall response rate of
30% as the target activity level and 10% as the lowest
overall response rate of interest. Our study was designed
to have 90% statistical power with a 5% Type I error.
With this design, 18 patients were enrolled at the first
stage. If there were 2 or fewer responses out of the
initial 18 patients, the study would conclude that the
anticipated response rate is less than 10% and terminate.
Otherwise, accrual continued to a total of 35 assessable
patients. At the second stage, at least 7 objective
responses among 35 patients were required for this regi-
men to be regarded as worthy of further investigation.
Considering 10% follow up loss, 39 eligible patients
would be enrolled. At the first stage, we observed a
remarkably high response rate of 71% (5 partial
responses among 7 patients). The protocol was therefore
amended to estimate the response rate in patients with
metastatic or recurrent esophageal cancer not only in
the second-line setting, but also in the first-line setting.
The response rate of the treatment was calculated as the
ratio of the number of complete and partial responders
to the total number of evaluable patients. A 95% confi-
dence interval for the response rate was computed
based on the binomial distribution function. Toxicity
profile was assessed as the ratio of the number of occur-
rence to the total number of evaluable patients. The sec-
ondary objectives included time to progression and
overall survival, which was estimated by the Kaplan-
Meier method. Overall survival time was calculated
from the first day of treatment to death or the last day
of follow-up. Progression-free survival time was calcu-
lated from the first day of treatment to the date that dis-
ease progression or death from any cause was reported.
Results
1. Patient Characteristics
Between February 2006 and February 2009, 32 patients
with metastatic or recurrent esophageal cancer were
enrolled at single institution. The baseline characteristics
of the patients are summarized in Table 1. Twelve
patients were chemotherapy-naïve. Twenty patients had
received prior therapy including a platinum based
regimen.
The median age was 60.5 years (range; 45 to 76 years)
and all patients were male. 97% of patients had an
ECOG performance status of 0-1. Ten patients (31.3%)
had undergone surgery. All patients were assessable for
efficacy and safety analyses.
2. Treatment Exposure
The median number of cycles of PACE administered to
patients was five for all patients. Reasons for treatment
discontinuation were as follows; 27 patients discontin-
ued therapy for disease progression, 2 patients for toxi-
city, 2 patients for non-compliance, and one patient
continues treatment at the time of final analysis. The
relative dose intensity of paclitaxel and capecitabine was
88.2% and 86.5%, respectively. The dose modifications
were performed in only 11 (6.1%) of 180 cycles adminis-
tered to all patients.
3. Efficacy
An overall response rate for the PACE regimen of 56.3%
(95% CI, 39.0 to 73.4) was observed and the disease con-
trol rate was 75.0% (Table 2). Three patients achieved
complete response (CR) and fifteen patients achieved
partial response (PR). Among twelve patients receiving
first-line treatment, two patients achieved CR and seven
patients achieved PR, giving an overall response rate of
75% (95% CI, 50.5 to 99.5). Among twenty patients
receiving second-line treatment, one patient achieved
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second-line PACE was 45% (95% CI, 23.2 to 66.8).
Among twenty patients treated with second-line therapy,
six patients (46.2%) who had a treatment free-interval of
< 3 months between their last chemotherapy and PACE
showed an objective response, which reflects the clinical
efficacy in patients whose tumors progress more rapidly
(Table 3). All twenty patients treated in the second-line
received platinum-based chemotherapy in the first-line
setting. With respect to prior chemotherapy received for
patients treated in the second-line, two patients out of
three treated with prior 5-FU/cisplatin and one patient
out of six treated with docetaxel/cisplatin achieved par-
tial responses to PACE. The clinical efficacy of PACE
seems to be more slightly lower in patients previously
treated with docetaxel, which suggest that paclitaxel
may have cross resistance to docetaxel (Table 4). How-
ever, any definitive conclusions can not be made due to
small sample size.
Median progression-free survival was 5.2 months (95%
CI, 4.0 to 6.5) (Figure 1) and median overall survival
(OS) was 11.7 months (95% CI, 5.5 to 18.0) for all
patients. The median OS was 14.3 months (95% CI, 10.6
to 18.0) for patients receiving therapy as 1
st line and 8.4
months (95% CI, 6.7 to 10.1) for those receiving as 2
nd-
line therapy (Figure 2).
4. Safety and Tolerability
All patients who received at least one cycle of study
treatment were evaluated for toxicity (n = 32). The most
Table 1 Patient baseline characteristics
Characteristics First-line Second-line All patients (%)
No (%) No (%)
Sex Male 12 (100) 20 (100) 32 (100)
Female 0 (0) 0 (0) 0 (0.0)
Age, median 58 (45-70) 66 (54-76) 60.5(45~76)
ECOG PS 0 3 (25) 6 (30) 9 (28.1)
1 9 (75) 13 (65) 22 (68.8)
2 0 (0) 1 (5) 1 (3.1)
Histology Squamous 12 (100) 20 (100) 32 (100)
Smoking history Never 0 (0) 2 (10) 2 (6.3)
Ever 12 (100) 18 (90) 30 (93.7)
Prior therapy None 6 (50) N/A 6
Surgery 6 (50) 4 (20) 10
Radiation 0 (0) 2 (10) 2
Chemotherapy N/A 20 (100) 20
No.of metastatic sites 1 3 (25.0) 5 (25) 8 (25.0)
2 3 (25.0) 10 (50) 13 (40.6)
3 1 (8.3) 4 (20) 5 (15.6)
Locoregional 5 (41.7) 1 (5) 6 (18.8)
Metastatic 7 (58.3) 19 (95) 26 (81.3)
Liver 3 (25.0) 13 (65) 16 (50.0)
Lung 7 (58.3) 19 (95) 26 (81.3)
Bone 2 (16.7) 5 (25) 7 (21.9)
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; N/A, Not applicable.
Table 2 Tumor response rate and survival according to
therapy line
Efficacy endpoints 1
st line
(n = 12)
2
nd line
(n = 20)
Overall
(n = 32)
No. (%) No. (%) No. (%)
Complete response 2 (16.7) 1 (5.0) 3 (9.4)
Partial response 7 (58.3) 8 (40.0) 15 (46.9)
Stable disease 0 (0.0) 6 (30.0) 6 (18.7)
Progressive disease 3 (25.0) 5 (25.0) 8 (25.0)
Overall response rate 9 (75.0) 9 (45.0) 18 (56.3)*
*(95%Confidence Interval; 39.0-73.4).
Table 3 Tumor response by treatment free-interval in
patients treated as second-line
Tumor Response Treatment free-interval (N = 20)
< 3 months 3-6 months > 6 months
No. (%) No. (%) No. (%)
Complete response 1 (7.7) 0 (0) 0 (0)
Partial response 5 (38.5) 1 (33) 3 (75)
Stable disease 2 (15.4) 2 (67) 1 (25)
Progressive disease 5 (38.5) 0 (0) 0 (0)
Total 13 (100) 3 (100) 4 (100)
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Table 5. Hematologic toxicity was common, with seven-
teen (53.1%) patients having grade 3-4 neutropenia and
two (6.3%) patients febrile neutropenia. The most com-
mon grade 3 to 4 non-hematologic adverse events were
stomatitis (n = 3), asthenia (n = 2), hand-foot syndrome
(n = 1), and peripheral neuropathy (n = 1). No grade 4
non-hematologic toxicity was observed and there was
no treatment-related death.
Discussion
This prospective, phase II study provides important
insights into the treatment of patients with esophageal
squamous cell carcinoma. PACE showed promising effi-
cacy, with an overall response rate of 75% as first-line,
45% as second-line and a median OS of 11.7 months.
Treatment was well-tolerated and toxicity was manage-
able. Dysphagia is a common symptom in esophageal
cancer, which may be cause of reduced number of eligi-
ble patients treated with capecitabine-based regimen.
However, during study period, patients otherwise eligible
who were excluded for dysphagia did not proceed the
screening process and screening failure due to dysphagia
was not observed. Oral administration of capecitabine is
feasible and more convenient compared with infusional
5-FU in esophageal cancer.
Treatment of metastatic esophageal cancer still
remains a serious challenge to medical oncologists. The
most frequently used chemotherapy regimen is a combi-
nation of 5-fluorouracil and cisplatin, with response
rates ranging from 20-45%. Recently, new agents such as
taxanes, vinorelbine, irinotecan, capecitabine, and oxali-
platin have been investigated as single agent or in com-
bination in esophageal cancer [6,14-17]. The results of
other phase II trials using various agents in esophageal
cancer are summarized in Table 6. Although direct
comparison is difficult across several trials due to differ-
ent clinicopathologic characteristics of patients, our
study shows at least comparable efficacy or better out-
comes than those of other studies.
Several capecitabine-based regimens were evaluated in
the first-line settings. Van Meerten et al [18] reported
that capecitabine and oxaliplatin was an active regimen
with a response rate of 39% and median OS of 8 months
in the first-line. In that study, 45 of 51 patients (88%)
had a histologic diagnosis of adenocarcinoma, whereas
all patients in our study had squamous cell histology.
Another study demonstrated the efficacy of oxaliplatin
and capecitabine in patients with esophageal squamous
cell carcinoma (ESCC), with a response rate of 43.8%
and a median OS of 10 months [19]. Although it is
known that there are biological differences between eso-
phageal adenocarcinoma and squamous cell cancer, clin-
ical efficacy of capecitabine and oxaliplatin is not
Table 4 Tumor response by prior regimen in patients
treated as second-line
Tumor Response Prior regimen (N = 20)
IP FP DP NP
Complete response 0 0 0 1
Partial response 4 2 1 2
Stable disease 1 1 2 1
Progressive disease 2 0 3 0
Total 73 6 4
Abbreviations: IP, Irinotecan/cisplatin; FP, 5-fluorouracil/cisplatin; DP,
docetaxel/cisplatin; NP, vinorelbine/cisplatin.
Figure 1 Kaplan-Meier curve of progression free survival for
patients treated as 1
st line and 2
nd line therapy.
)LJXUH
Figure 2 Kaplan-Meier curve of overall survival for patients
treated as 1
st line and 2
nd line therapy.
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Page 5 of 9Table 5 Hematologic and non-hematologic toxicity (NCI-CTC version 3.0)
Toxicity NCI-CTC Grade (n = 32)
01234
No. (%) No. (%) No. (%) No. (%) No. (%)
Hematologic
Leukocytopenia 4 (12.5) 9 (28.1) 11 (34.4) 8 (25.0) 0 (0.0)
Neutropenia 5 (15.6) 3 (9.4) 7 (21.9) 10 (31.3) 7 (21.9)
Anemia 1 (3.1) 12 (37.5) 17 (53.1) 2 (6.3) 0 (0.0)
Thrombocytopenia 28 (87.5) 4 (12.5) 0 (0.0) 0 (0.0) 0 (0.0)
Non-hematologic
Neurology Neuropathy 18 (56.3) 8 (25.0) 5 (15.6) 1 (3.1) 0 (0.0)
GI Stomatitis 13 (40.6) 12 (37.5) 4 (12.5) 3 (9.4) 0 (0.0)
Anorexia 10 (31.3) 17 (53.1) 5 (15.6) 0 (0.0) 0 (0.0)
Nausea/Vomiting 16 (50.0) 16 (50.0) 0 (0.0) 0 (0.0) 0 (0.0)
Constipation 23 (71.9) 6 (18.8) 3 (9.4) 0 (0.0) 0 (0.0)
Diarrhea 24 (75.0) 7 (21.9) 1 (3.1) 0 (0.0 0 (0.0)
Hepatic AST↑ 27 (84.4) 4 (12.5) 1 (3.1) 0 (0.0) 0 (0.0)
ALT↑ 29 (90.6) 3 (9.4) 0 (0.0) 0 (0.0) 0 (0.0)
Bilirubin↑ 25 (78.1) 6 (18.8) 1 (3.1) 0 (0.0) 0 (0.0)
Renal Creatinine↑ 23 (71.9) 8 (25.0) 1 (3.1) 0 (0.0) 0 (0.0)
Dermatology Alopecia 5 (15.6) 16 (50.0) 11 (34.4) 0 (0.0) 0 (0.0)
Rash 25 (78.1) 5 (15.6) 2 (6.3) 0 (0.0) 0 (0.0)
Itching 27 (84.4) 5 (15.6) 0 (0.0) 0 (0.0) 0 (0.0)
Hyperpigmentation 20 (62.5) 10 (31.3) 2 (6.3) 0 (0.0) 0 (0.0)
Nail change 24 (75.0) 3 (9.4) 4 (12.5) 1 (3.1) 0 (0.0)
Hand-foot syndrome 18 (56.3) 9 (28.1) 4 (12.5) 1 (3.1) 0 (0.0)
Others Asthenia 8 (25.0) 16 (50.0) 6 (18.8) 2 (6.3) 0 (0.0)
Myalgia 23 (71.9) 8 (25.0) 1 (3.1) 0 (0.0) 0 (0.0)
Febrile neutropenia 30 (93.8) 0 (0.0) 0 (0.0) 2 (6.3) 0 (0.0)
Pneumonitis 30 (93.8) 1 (3.1) 0 (0.0) 1 (3.1) 0 (0.0)
Table 6 Results of phase II trials in esophageal cancer
Author Regimen Histology Therapy line Response rate (%) TTP/PFS OS
Lee [20] XP (X:2,500 mg/m
2 D1-14
CDDP:60 mg/m
2; D1)
SCC
(n = 45)
1
st line
(n = 45)
57.8% 4.7 mon 11.2 mon
Van Meerten [18] XELOX
(X:2,000 mg/m
2 D1-14
O:130 mg/m
2; D1)
ADC (n = 45)
SCC (n = 4)
Undiff. (n = 2)
1
st line
(n = 51)
39% NR 8 mon
MB Polee [28] Paclitaxel:180 mg/m
2;D1
CDDP:60 mg/m
2;D 1
ADC (n = 31)
SCC (n = 16)
Undiff (n = 4)
1
st line
(n = 51)
ADC (39%)
SCC (44%)
NR 9 mon
Zhang [29] Paclitaxel:175 mg/m
2 on D1
CDDP:75 mg/m
2 (D1)
SCC
(n = 35)
1
st line
(n = 35)
48.6% 7 mon 13 mon
S.Lorenzen [21] DX
(X:2,000 mg/m
2 D1-14
D:75 mg/m
2; D1)
ADC (n = 7)
SCC (n = 17)
1
st (n = 16)
2
nd (n = 8)
1
st (56%)
2
nd (25%)
Overall = 46%
6.1 mon 1
st (15.8)
2
nd (6.2)
S.Lorenzen [26] FP + Cetuximab vs
FP
SCC (n = 62) 1
st line
(n = 62)
FP+ Cetuximab (19%)
FP (13%)
5.9 mon
3.6 mon
9.5 mon
5.5 mon
Current Study Xeloda 1,800 mg/m
2 D1-14
Paclitaxel:80 mg/m
2 on D1, D8
SCC (n = 32) 1
st (n = 12)
2
nd (n = 20)
1
st (75%)
2
nd (45%)
Overall = 53.6%
5.23 mon
4.54 mon
14.3 mon
8.4 mon
Abbreviations: XP, capecitabine/cisplatin; XELOX, capecitabine/oxaliplatin; DX, docetaxel/capecitabine; FP, 5-fluorouracil/cisplatin; SCC, squamous cell carcinoma;
ADC, adenocarcinoma; Undiff, undifferentiated carcinoma; TTP, time to progression; PFS, progression-free survival; OS, overall survival; NR, not reported.
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carcinoma of the esophagus. Lee et al [20] also reported
the results of cisplatin and capecitabine (XP) in ESCC.
The response rate was 57.8% and median OS was 11.2
months. The authors concluded that the XP regimen
was a promising combination chemotherapy in meta-
static esophageal squamous cell carcinoma with a toler-
able toxicity profile. Another docetaxel/capecitabine trial
reported a response rate of 46% and median survival of
15.8 months [21]. However the incidence of hand-foot
syndrome (HFS) and diarrhea was higher than that of
our study, which can be explained by the lower dose of
capecitabine (900 mg/m
2 twice daily) in our study.
Another explanation for lower rate of HFS in our study
is that the risk factors for HFS have been reported to
include use of docetaxel chemotherapy and ethnic dif-
ferences may also contribute to the occurrence of HFS
[22]. Randomized phase II study of weekly docetaxel (30
mg/m
2) on days 1 and 8 and capecitabine (1600 mg/m
2
per day) on days 1-14 showed a response rate of 26%,
median PFS of 4.6 months, and OS of 10.1 months in
patients with esophagogastric cancer. However, in this
study, only 36% of patients were esophageal cancers and
16% of patients had squamous cell carcinoma. The con-
firmed response rate was 26%, which was lower than
that of our study, in which only unconfirmed response
rate was reported. The more than grade 3 HFS was
observed in 5% of patients treated with docetaxel and
capecitabine [23].
Paclitaxel-based regimens were evaluated in patients
with esophageal cancer. The result of a phase II trial of
paclitaxel and nedaplatin as first line chemotherapy for
advanced esophageal cancer was reported, with a
response rate of 41.7%, median time to progression of
6.1 months and median overall survival of 11.5 months
[24]. In this study, 46 of 48 patients had squamous cell
histology and 2 patients had adenocarcinomas. Another
study using paclitaxel and nedaplatin as first line therapy
showed that the overall response rate was 43.6%, median
progression-free survival and median overall survival
was 6.1 and 10.3 months, respectively [25]. Among 39
enrolled patients, 36 (92.3%) had squamous cell carci-
noma. Similar to metastatic disease, in unresectable
locally advanced esophageal cancer (squamous/adeno-
carcinoma; 36/14), definitive concurrent chemoradiation
with weekly paclitaxel and carboplatin also showed pro-
mising efficacy with OS of 17 months and median time
to local progression of 14 months, which demonstrated
high clinical activity of paclitaxel-based regimen.
However, median overall survival rarely exceeds 12
months despite the improvement of chemotherapy regi-
mens and supportive care in metastatic esophageal squa-
mous cell carcinoma. There are several strategies to
improve the overall survival of metastatic solid tumors,
such as adding another cytotoxic agent to doublet regi-
men, thus using triplet therapies and adding molecular
targeted agents to cytotoxic chemotherapy. As shown in
many solid tumors, several clinical trials with triplet
chemotherapy (taxane, platinum and 5-FU) demon-
strated no superiority to historical doublet chemother-
apy regimens in metastatic esophageal cancer,[2]
although no direct comparison is possible across the
trials. Regarding molecular targeted agents, a rando-
mized phase II study comparing the epidermal growth
factor receptor (EGFR) inhibitor, cetuximab in combina-
tion with 5-FU and cisplatin (FC), with FC alone was
conducted to evaluate the efficacy and safety in first-line
metastatic squamous cell carcinoma of the esophagus
[26]. The median PFS (5.9 versus 3.6 months) and the
median OS (9.5 versus 5.5 months) both favored the
cetuximab plus FC combination, but the median OS of
9.5 months was disappointing despite the addition of
cetuximab to chemotherapy, considering the median OS
ranging between 8 and 15 months reported in several
phase II trials with chemotherapy alone [6,20,21,27].
Maintaining quality of life (QOL) and symptom relief
are important factors in the management of patients
with metastatic solid tumors. In this study, we did not
evaluate QOL, including dysphagia, during study period,
but the toxicities were generally well-tolerated for most
patients. The most common reason for treatment dis-
continuation was disease progression, whereas only two
patients stopped therapy due to toxicity.
Compared with other studies, the observed response
rate, although not confirmed at least 4 weeks after initial
response evaluation, was higher than our expectations at
the time of study design despite administering treatment
as second-line therapy, so the patients who were not
previously treated with any chemotherapy were also
included in this study. However, although change of
patients population was another weak point of our
study, at the first stage, we observed a remarkably high
response rate of 71% (5 partial responses among 7
patients) and considering that the incidence of esopha-
geal cancer is relatively low and patients recruitment
was slow, we enrolled the patients in the first-line set-
ting. With regard to protocol amendment, we did not
consider statistical correction.
The median OS was 14.3 months for patients receiv-
ing therapy as 1
st-line and 8.4 months for those receiv-
ing as 2
nd-line therapy. Although the small sample size
of patients treated as 1
st-line makes it difficult to draw
definitive conclusions, this regimen deserves further eva-
luation as front-line treatment for esophageal cancer
considering the high clinical activity observed in our
study.
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Weekly paclitaxel and capecitabine treatment as first-
and second-line therapy is highly active and well-toler-
ated in patients with advanced esophageal squamous
cell carcinoma. Non-platinum based doublet chemother-
apy showed significant clinical benefit in our study, and
further studies using non-platinum-based chemotherapy
are warranted for the treatment of esophageal cancer.
Ultimately, randomized clinical trials are needed to
determine the efficacy and safety of paclitaxel and cape-
citabine for esophageal cancer patients.
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